Meihekou Central Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT05152355
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

4.Meihekou Central Hospital | Meiheko Central Hospital | Meihekou Central Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

budesonide (rhinocort) (1 trial)

Drugs in Phase 3 Trials (3)

borneol (1 trial)

ferric citrate (AURYXIA) (1 trial)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperphosphatemia (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4